Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer

Anita C. Thomas; Marcella J. Wyatt; Andrew C. Newby

doi:10.1160/TH08-11-0772

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2009; 102(01): 145-152
DOI: 10.1160/TH08-11-0772

Animal Models

Schattauer GmbH

Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer

Anita C. Thomas

¹Bristol Heart Institute, University of Bristol, Bristol, United Kingdom

²Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia

,

Marcella J. Wyatt

¹Bristol Heart Institute, University of Bristol, Bristol, United Kingdom

,

Andrew C. Newby

¹Bristol Heart Institute, University of Bristol, Bristol, United Kingdom

› Institutsangaben

Abstract

Summary

Vein grafts are used to bypass coronary arterial stenosis, but many grafts thrombose soon after surgery. A model was developed in the pig to allow continuous measurement of blood flow and production of flow-restricting thrombi (cyclic flow reductions; CFRs). Saphenous vein lumen was exposed to adenovirus ex vivo, to over-express human tissue plasminogen activator (h-tPA), with β-galactosidase adenovirus as a control. The vein segmen ts were engrafted into carotid arteries and examined 0,1 or 3 days later (4–7 animals/group). Untransduced grafts examined on the day of surgery developed repeated CFRs at both normal and restricted flow, but their frequency declined in grafts examined after 3 days. Adenovirus transduction was evident as β-galactosidase or h-tPA expression 1 day after engraftment. Blood flow was increased 1.4-fold in h-tPA transduced grafts after 1 day [control 390 (280–510), h-tPA 550 (450–660) ml/min; p=0.02 (expressed as mean (95% confidence intervals)]. CFRs were less severe (p=0.002) in the h-tPA transduced grafts than β-galactosidase-transduced grafts. CFRs were also less frequent in unstenosed undamaged h-tPA grafts [control 17 (6.1–29), h-tPA 7.6 (1.7–14) CFR/hr; p=0.02], but this difference was reduced after damage or stenosis. CFRs formed faster in h-tPA than in β-galactosidase-transduced grafts [control 14 (11–17), h-tPA 23 (19–27) ml/min²; p<0.001], and resolved twofold faster [control 25 (22–30), h-tPA 48 (39–60) ml/min2; p<0.001]. Hence, in this model, local gene therapy with h-tPA increased graft blood flow and decreased measures of early graft thrombosis, namely quicker CFR resolution and decreased frequency and severity.

Keywords

Vein graft - tissue plasminogen activator - acute thrombosis - gene therapy - animal model

Volltext

Referenzen

References
1 Angelini GD, Newby AC. The future of saphenous vein as a coronary artery bypass conduit. Eur Heart J 1989; 10: 273-280.
2 Baker AH, Mehta D, George SJ. et al. Prevention of vein graft failure: potential applications for gene therapy. Cardiovasc Res 1997; 35: 442-450.
3 Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97: 916-931.
4 White SJ, Newby AC. Gene therapy for all aspects of vein-graft disease. J Card Surg 2002; 17: 549-555.
5 Underwood MJ, Cooper G, More R. et al. Effect of intraluminal application of tissue-type plasminogen activator on the fibrinolytic activity of experimental vein grafts. Cardiovasc Res 1995; 29: 422-427.
6 Manchio JV, Gu J, Romar L. et al. Disruption of graft endothelium correlates with early failure after offpump coronary artery bypass surgery. Ann Thorac Surg 2005; 79: 1991-1998.
7 Kauhanen P, Siren V, Carpen O. et al. Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure. Circulation 1997; 96: 1783-1789.
8 Poston RS, Gu J, Brown JM. et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006; 131: 122-130.
9 Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 83: IV3-14.
10 Folts JD. Drugs for the prevention of coronary thrombosis: From an animal model to clinical trials. Cardiovasc Drugs Ther 1995; 09: 31-43.
11 Strony J, Beaudoin A, Brands D. et al. Analysis of shear stress and hemodynamic factors in a model of coronary artery stenosis and thrombosis. Am J Physiol 1993; 265: H1787-H1796.
12 Anderson HV, Kirkeeide RL, Krishnaswami A. et al. Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol 1994; 23: 1031-1037.
13 George SJ, Lloyd CT, Angelini GD. et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000; 101: 296-304.
14 Angelini GD, Bryan AJ, Williams HM. et al. Distention promotes platelet and leukocyte adhesion and reduces short-term patency in pig arteriovenous bypass grafts. J Thorac Cardiovasc Surg 1990; 99: 433-439.
15 Carmeliet P, Stassen JM, van Vlaenderen I. et al. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissuetype plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood 1997; 90: 1527-1534.
16 Wilkinson GW, Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res 1992; 20: 2233-2239.
17 Lee BY, Assadi C, Madden JL. et al. Hemodynamics of arterial stenosis. World J Surg 1978; 02: 621-627.
18 Golino P, Cirillo P, Calabro P. et al. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. J Am Coll Cardiol 2001; 38: 569-576.
19 Emeis JJ, van den Eijnden-Schrauwen, van den Hoogen CM. et al. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997; 139: 245-256.
20 Eckstein RW, Gregg DE, Pritchard W. The magnitude and time of development of the collateral circulation in occluded femoral, carotid and coronary arteries. Am J Physiol 1941; 132: 351-361.
21 Waugh JM, Kattash M, Li J. et al. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci USA 1999; 96: 1065-1070.
22 Kimura H, Sakata Y, Hamada H. et al. In vivo retention of endothelial cells adenovirally transduced with tissue-type plasminogen activator and seeded onto expanded polytetrafluoroethylene. J Vasc Surg 2000; 32: 353-363.
23 Siren V, Kauhanen P, Carpen O. et al. Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis. Blood Coagul Fibrinolysis 2003; 14: 369-377.
24 Hilfiker PR, Waugh JM, Li-Hawkins JJ. et al. Enhancement of neointima formation with tissue-type plasminogen activator. J Vasc Surg 2001; 33: 821-828.
25 Jiang X, Liu X, Zhang K. et al. Experimental study of tissue-type plasminogen activator gene to prevent vein grafts stenosis. J Huazhong Univ Sci Technolog Med Sci 2006; 26: 314-316.
26 Burggraf D, Martens HK, Dichgans M. et al. Matrix metalloproteinase (MMP) induction and inhibition at different doses of recombinant tissue plasminogen activator following experimental stroke. Thromb Haemost 2007; 98: 963-969.
27 Torsney E, Mayr U, Zou Y. et al. Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. Circ Res 2004; 94: 1466-1473.
28 Nassar T, Akkawi S, Shina A. et al. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood 2004; 103: 897-902.
29 Mutch NJ, Moir E, Robbie LA. et al. Localization and identification of thrombin and plasminogen activator activities in model human thrombi by in situ zymography. Thromb Haemost 2002; 88: 996-1002.
30 Davies MG, Klyachkin ML, Dalen H. et al. The integrity of experimental vein graft endothelium--implications on the etiology of early graft failure. Eur J Vasc Surg 1993; 07: 156-165.
31 Bourassa MG, Campeau L, Lesperance J. et al. Changes in grafts and coronary arteries after saphenous vein aortocoronary bypass surgery: results at repeat angiography. Circulation 1982; 65: 90-97.